Clinical Trials Arena on MSN14h
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback